NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 2;97(3):188-94. https://doi.org/10.1093/jnci/dji021

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. https://doi.org/10.1016/S0140-6736(13)62422-8

von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. https://doi.org/10.1093/jnci/djn085

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018 Jul 12;379(2):111-21. https://doi.org/10.1056/NEJMoa1804710

Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. https://doi.org/10.1200/JCO.2007.15.0235. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. https://doi.org/10.1200/JCO.2014.57.0572

Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary AnalysisoftheGeparSixtoRandomizedClinicalTrial. JAMAOncol. 2017 Oct 1;3(10):1378-85. https://doi.org/10.1001/jamaoncol.2017.1007

Gray R, Bradley R, Braybrooke J, Davies C, Pan H, Peto R, et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. 2017 San Antonio Breast Cancer Symposium. Abstract GS1-01. Presented December 6, 2017. http://dx.doi.org/10.1158/1538-7445.SABCS17-GS1-01

Gianni L, Pienkowski T, Im YH, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a

randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan;13(1):25-32. https://doi.org/10.1016/S1470-

(11)70336-9

Masuda N, Lee SJ, Ohtani S, Im YH, Lee E-S, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-59. https://doi.org/10.1056/NEJMoa1612645

Tolaney SM, Barry WT, Guo H, Dillon D, Dang CT, Yardley DA, et al. Seven-year (yr) follow-up of adjuvant paclitaxel

(T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Proc Am Soc Clin Oncol. 2017:511. https://doi.org/10.1200/JCO.2017.35.15_suppl.511

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21- Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol. 2016 Jul 10;34(20):2341-9. https://doi.org/10.1200/JCO.2015.63.5383